| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66321267cc111d80e6bcb25e359298fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_327b96706bd46f045482a324c965bfa5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0ad1dd791e58a42eb3ab87475d91459 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-315 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
2010-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afecec42c76186a8d418d35fcbe91df5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6882ac3381d2bd4df626980ec45b03e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b3d36e524a8bef7bb814d97b45af059 |
| publicationDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010291024-A1 |
| titleOfInvention |
Methods and compositions for the treatment of proliferative and pathogenic diseases |
| abstract |
The invention features peptide fragments containing domain 4 of the Streptococcus intermedius intermedilysin (ILY) protein and the use of these fragments to sensitize cancer cells to antibody-based anticancer treatments. The invention also features use of these fragments to treat patients infected with microbial pathogens expressing CD59 or CD59-like molecules. CD59 receptor activity has been associated with decreased sensitivity to therapeutic and endogenously produced antibodies. Administration of ILY domain 4 polypeptides is sufficient to inhibit CD59 receptor activity while avoiding the general toxicity associated with full length ILY. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9933427-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015344976-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10495641-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9617607-B2 |
| priorityDate |
2007-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |